ロード中...
Author response to Colle et al
The event of pseudoprogression is rare in patients with MSI-high metastatic colorectal cancer receiving immune checkpoint inhibitors. In this response to the Letter to the Editor by Colle et al, we highlight that the timing of disease re-assessment may influence the incidence of pseudoprogression, w...
保存先:
| 出版年: | J Immunother Cancer |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8231051/ https://ncbi.nlm.nih.gov/pubmed/34162717 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-003138 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|